Abbvie partners with Genmab in $750 million cancer therapy deal

[June 10, 2020]  (Reuters) - Abbvie Inc said on Wednesday it has entered into an agreement with Genmab AS to jointly develop and commercialize cancer treatment.

Under the terms of the agreement, AbbVie will pay Genmab $750 million in upfront payment and Genmab could receive up to $3.15 billion in additional development, regulatory and sales milestone payments.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.